Flexion Therapeutics Announces Clinical Hold Of FX006 Phase 2B Clinical Trial In Osteoarthritis Of The Knee

By: via Benzinga
Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that the United States Food and Drug Administration (FDA) informed the company ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.